# Hazelnut Blood Lipids Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/hazelnut-blood-lipids-randomized-trial-evidence-review
Category: evidence-review
Summary: Hazelnut Blood Lipids Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are 
Last reviewed: 2026-08-05
Reviewed by: Migaku Evidence Review
# Hazelnut Blood Lipids Randomized Trial: What the Evidence Says

## Quick Answer

Hazelnut Blood Lipids Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Nut consumption in chronic kidney disease: a systematic review | systematic review | 1 | 2025-11-10 | 10.3389/fnut.2025.1659516 |
| Walnut Consumption May Contribute to Healthy Cardiovascular/Endothelial Function by Maintaining Membrane Integrity | narrative review | 3 | 2024-11-05 | 10.3390/life14111426 |

## What The Sources Report

- Traditional risk factors for CKD development and progression include diabetes, hypertension, and obesity. [Lazzarin Taline (2025); evidence level 1]
- In particular, inflammation and oxidative stress contribute to vascular injury, endothelial dysfunction, and accelerated atherosclerosis, which markedly increase the risk of cardiovascular morbidity and mortality in this population. [Lazzarin Taline (2025); evidence level 1]
- Previous studies have provided ample evidence that a healthy diet has an important role in delaying the development of many modifiable risk factors of CVD, including abdominal obesity, high blood pressure, abnormally high cholesterol and blood glucose levels. [Jarai Dora (2024); evidence level 3]
- This surge in production reflects increased global demand, likely influenced by the recognized health benefits of walnut consumption. [Jarai Dora (2024); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For hazelnut blood lipids randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Lazzarin Taline (2025). Nut consumption in chronic kidney disease: a systematic review. DOI: 10.3389/fnut.2025.1659516. PMCID: PMC12642863. PMID: 41293182. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12642863/
- Jarai Dora (2024). Walnut Consumption May Contribute to Healthy Cardiovascular/Endothelial Function by Maintaining Membrane Integrity. DOI: 10.3390/life14111426. PMCID: PMC11595550. PMID: 39598224. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC11595550/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.